Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Abstract

Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.

Keywords

DNA damage response / PI3K/AKT / chemotherapy / resistance / AML

References

[1] Döhner H,Bloomfield CD.Acute myeloid leukemia.N Engl J Med2015;373:1136-52

[2] Döhner H,Grimwade D.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood2017;129:424-47 PMCID:PMC5291965

[3] Dombret H.An update of current treatments for adult acute myeloid leukemia.Blood2016;127:53-61 PMCID:PMC4705610

[4] Theilgaard-Mönch K,Ferrari S.Gene expression profiling in MDS and AML: potential and future avenues.Leukemia2011;25:909-20

[5] Papaemmanuil E,Bullinger L.Genomic classification and prognosis in acute myeloid leukemia.N Engl J Med2016;374:2209-21 PMCID:PMC4979995

[6] Park S,Tamburini J.Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.Haematologica2010;95:819-28 PMCID:PMC2864389

[7] Frelin C,Griessinger E.Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.Blood2005;105:804-11

[8] Bouwman P.The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.Nat Rev Cancer2012;12:587-98

[9] Blackford AN.ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response.Mol Cell2017;66:801-17

[10] Pilié PG,Mills GB.State-of-the-art strategies for targeting the DNA damage response in cancer.Nat Rev Clin Oncol2019;16:81-104 PMCID:PMC8327299

[11] Dobbelstein M.Exploiting replicative stress to treat cancer.Nat Rev Drug Discov2015;14:405-23

[12] Darici S,Horne G,Marmiroli S.Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence.J Clin Med2020;9:2934 PMCID:PMC7563273

[13] Janku F,Meric-Bernstam F.Targeting the PI3K pathway in cancer: are we making headway?.Nat Rev Clin Oncol2018;15:273-91

[14] Song M,Dong Z.AKT as a therapeutic target for cancer.Cancer Res2019;79:1019-31

[15] Nepstad I,Grønningsæter IS.The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells.Int J Mol Sci2020;21:2907 PMCID:PMC7215987

[16] Janku F.Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients.Cancer Treat Rev2017;59:93-101

[17] Reuvers TGA,Nonnekens J.DNA damage-inducing anticancer therapies: from global to precision damage.Cancers (Basel)2020;12:2098 PMCID:PMC7463878

[18] Huang TT,Coots C.Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.Cancer Treat Rev2020;86:102021 PMCID:PMC7272282

[19] Jackson SP.DNA REPAIR. Drugging DNA repair.Science2016;352:1178-9

[20] Fruman DA,Hopkins BD,Cantley LC.The PI3K pathway in human disease.Cell2017;170:605-35 PMCID:PMC5726441

[21] Liu Q,Alfred Yung WK,Zhang W.Role of AKT signaling in DNA repair and clinical response to cancer therapy.Neuro Oncol2014;16:1313-23 PMCID:PMC4165418

[22] Gewirtz D.A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.Biochemical Pharmacology1999;57:727-41

[23] Dombret H,Butrym A.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood2015;126:291-9 PMCID:PMC4504945

[24] DiNardo CD,Pullarkat V.Azacitidine and venetoclax in previously untreated acute myeloid leukemia.N Engl J Med2020;383:617-29

[25] Aldoss I,Aribi A.Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.Haematologica2018;103:e404-7 PMCID:PMC6119155

[26] Pastore D,Carluccio P.FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.Ann Hematol2003;82:231-5

[27] Stahl M,Montesinos P.Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.Blood Adv2018;2:923-32 PMCID:PMC5916007

[28] Menolfi D.ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion.Cell Biosci2020;10:8

[29] Mateo J,Sandhu S.DNA-Repair defects and olaparib in metastatic prostate cancer.N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[30] Batey MA,Kyle S.Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.Mol Cancer Ther2013;12:959-67 PMCID:PMC3736091

[31] Foote KM,Cronin A.Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.J Med Chem2013;56:2125-38

[32] Fok JHL,Vazquez-Chantada M.AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.Nat Commun2019;10:5065 PMCID:PMC6838110

[33] Leijen S,Sonke GS.Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months.J Clin Oncol2016;34:4354-61

[34] Riches LC,Hughes G.Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically.Mol Cancer Ther2020;19:13-25

[35] Fordham SE,Elstob CJ.Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.Blood Adv2018;2:1157-69 PMCID:PMC5965047

[36] Ma J,Su Y.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.Sci Rep2017;7:41950 PMCID:PMC5296912

[37] Palii SS,Sankpal UT,Robertson KD.DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.Mol Cell Biol2008;28:752-71 PMCID:PMC2223421

[38] Lukas J,Bartek J.More than just a focus: the chromatin response to DNA damage and its role in genome integrity maintenance.Nat Cell Biol2011;13:1161-9

[39] Colell MH,Blätte TJ. Molecular profiles in AML patients older than 70 years of age. Abstract PF213. Available from: https://library.ehaweb.org/eha/2018/stockholm/214704/montserrat.hoyos.colell.molecular.profiles.in.aml.patients.older.than.70.years.html?f=media=1*listing=3*browseby=8 [Last accessed on 4 Nov 2021]

[40] Gerstung M,Martincorena I.Precision oncology for acute myeloid leukemia using a knowledge bank approach.Nat Genet2017;49:332-40 PMCID:PMC5764082

[41] Bullinger L,Döhner H.Genomics of acute myeloid leukemia diagnosis and pathways.J Clin Oncol2017;35:934-46

[42] Rapin N,Jendholm J.Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.Blood2014;123:894-904

[43] Xu Q,Scialla TJ,Carroll M.Survival of acute myeloid leukemia cells requires PI3 kinase activation.Blood2003;102:972-80

[44] Fujino T,Sugiura Y.Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.Nat Commun2021;12:1826 PMCID:PMC7988019

[45] Min YH,Cheong JW.Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable.Leukemia2003;17:995-7

[46] Pardee TS,Lowe SW.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.Exp Hematol2011;39:473-85.e4 PMCID:PMC3062750

[47] Dos Santos C,Ho YW.The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.Blood2013;122:1900-13 PMCID:PMC4968345

[48] Gallay N,Cuzin L.The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.Leukemia2009;23:1029-38

[49] Chen P,Fu Q.Induction of multidrug resistance of acute myeloid leukemia cells by cocultured stromal cells via upregulation of the PI3K/Akt signaling pathway.Oncol Res2016;24:215-23 PMCID:PMC7838662

[50] Fedele CG,Ho M.Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.Proc Natl Acad Sci U S A2010;107:22231-6 PMCID:PMC3009830

[51] Badura M,Zavadil J.DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs.Proc Natl Acad Sci U S A2012;109:18767-72 PMCID:PMC3503184

[52] Musa F,David-West G,Blank SV.Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer.Mol Cancer Ther2016;15:1557-67 PMCID:PMC5323079

[53] Li W,Lang J.Targeting mouse double minute 2: current concepts in DNA damage repair and therapeutic approaches in cancer.Front Pharmacol2020;11:631 PMCID:PMC7232544

[54] Wang JM,Chen W,Yen JJ.The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB.Mol Cell Biol1999;19:6195-206 PMCID:PMC84561

[55] Pugazhenthi S,Sable C.Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein.J Biol Chem2000;275:10761-6

[56] Tonic I,Park Y,Hay N.Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci.J Biol Chem2010;285:23790-8 PMCID:PMC2911328

[57] Pilling AB.Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.Prostate2019;79:1347-59 PMCID:PMC6617752

[58] Rahmani M,Habibi JR.The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.Blood2009;114:4507-16 PMCID:PMC2777129

[59] Rahmani M,Hawkins E.Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells.Cancer Res2018;78:3075-86 PMCID:PMC5984704

[60] Bozulic L,Hynx D.PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival.Mol Cell2008;30:203-13

[61] Park J,Li Y,Brazil DP.DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif.J Biol Chem2009;284:6169-74

[62] Halaby MJ,He J.ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells.Cell Signal2008;20:1555-63

[63] Lamm N,Cesare AJ.The mTOR pathway: implications for DNA replication.Prog Biophys Mol Biol2019;147:17-25

[64] Paschka P,Ruppert AS.Cancer and Leukemia Group BAdverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.J Clin Oncol2006;24:3904-11

[65] Yui S,Yamaguchi H.D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.Ann Hematol2017;96:1641-52

[66] Park SH,Cho YU,Park CJ.Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.Leuk Res2013;37:784-9

[67] Schnittger S,Haferlach T.KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.Blood2006;107:1791-9

[68] Estruch M,Vittori C.Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.Leukemia2021;35:2030-42

[69] Ueno Y,Kamiyama Y.Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD⁺ acute myeloid leukemia.Oncotarget2019;10:2530-45 PMCID:PMC6493465

[70] Munster PN,Nemunaitis JJ.Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.J Clin Oncol2016;34:2505

[71] Konstantinopoulos PA,Wahner Hendrickson AE.Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020;21:957-68 PMCID:PMC8023719

[72] Ragon BK,Jabbour E.Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.Am J Hematol2017;92:7-11 PMCID:PMC5361214

[73] Stone RM,Döhner H.Midostaurin in FLT3-mutated acute myeloid leukemia.N Engl J Med2017;377:1903

[74] Wang ES,Minden MD. Phase 3, Multicenter, Open-label study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. 62nd ASH Annual Meeting and Exposition; 2020 Dec 5-8. Available from: https://ash.confex.com/ash/2020/webprogram/Paper137708.html [Last accessed on 1 Nov 2021]

[75] Altman JK,Pratz KW,Cortes JE.Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.Am J Hematol2018;93:213-21 PMCID:PMC6586071

[76] Zelenetz AD,Brown JR.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol2017;18:297-311 PMCID:PMC5589180

[77] Murthy RK,Okines A.Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer.N Engl J Med2020;382:597-609

[78] Castaigne S,Terré C.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Lancet2012;379:1508-16

[79] Stein EM,Fathi AT.Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Blood2021;137:1792-803 PMCID:PMC8020270

[80] DiNardo CD,Stein EM.Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia.J Clin Oncol2021;39:57-65 PMCID:PMC7771719